Neo Medical SA received certification under the EU Medical Device Regulation for its entire portfolio of spine surgical ...

The U.S. Food and Drug Administration has approved a drug developed at Stanford Medicine that offers hope to people diagnosed ...

During a busy day of dealmaking, Cour Pharmaceutical Development Co. Inc. entered a pact with Roche Holding AG’s Genentech ...

If granted, Tremfya will be approved to treat children ages six and under with severe plaque psoriasis and children ages five ...

11/23，FDA 批准 BridgeBio Pharma $BridgeBio Pharma(BBIO)$ 的 Attruby (acoramidis) 用于降低转甲状腺素蛋白淀粉样心肌病 (ATTR-CM) 患者的心血管死亡和心血管相关住院率，与辉瑞的 tafamidis 展开直接竞争，后者具有相同的作用机制，但批准的适应症更有限。 Attruby 是一种口服 TTR 稳定剂，FDA的批准称该 ...

Among important regulatory news last week, US drugmaker BridgeBio Pharma gained Food and Drug Administration (FDA) approval ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

Whoever says the Food and Drug Administration is too cozy with Big Pharma isn’t paying attention to the bonanza of new ...

马萨诸塞州剑桥市 - Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)的执行副总裁兼首席财务官Jeffrey V.

马萨诸塞州剑桥市 - 根据向美国证券交易委员会提交的文件,Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)的执行副总裁兼首席商务官Tanguler Tolga最近出售了该公司的普通股。这些交易发生在2024年11月26日,涉及以247.77美元至252.27美元的价格出售1,469股股票,总计约368,685美元。

Kronos is cutting 83% of its workforce, while Idorsia is considering eliminating as many as 270 jobs. Elsewhere, PTC ...